Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$4.69 - $9.84 $99,897 - $209,592
-21,300 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$8.44 - $16.89 $78,610 - $157,313
9,314 Added 77.71%
21,300 $198,000
Q4 2021

Feb 09, 2022

BUY
$14.7 - $19.89 $176,194 - $238,401
11,986 New
11,986 $189,000
Q2 2021

Aug 12, 2021

SELL
$12.89 - $16.58 $394,434 - $507,347
-30,600 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$14.0 - $20.72 $428,400 - $634,032
30,600 New
30,600 $439,000
Q3 2020

Nov 12, 2020

SELL
$11.92 - $15.87 $154,960 - $206,310
-13,000 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$7.53 - $14.93 $97,890 - $194,090
13,000 New
13,000 $189,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Alpha Crest Capital Management LLC Portfolio

Follow Alpha Crest Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Crest Capital Management LLC with notifications on news.